tiprankstipranks
Trending News
More News >
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
US Market

Palvella Therapeutics (PVLA) Ratios

Compare
704 Followers

Palvella Therapeutics Ratios

PVLA's free cash flow for Q3 2025 was $0.00. For the 2025 fiscal year, PVLA's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
6.49 3.20 2.86--
Quick Ratio
6.49 3.20 2.86--
Cash Ratio
6.16 3.11 2.78--
Solvency Ratio
-1.32 1.64 -0.69--
Operating Cash Flow Ratio
-0.83 -5.81 -2.57--
Short-Term Operating Cash Flow Coverage
0.00 0.00 0.00--
Net Current Asset Value
$ 38.68M$ -3.88M$ -23.17M--
Leverage Ratios
Debt-to-Assets Ratio
0.00 0.00 0.00--
Debt-to-Equity Ratio
0.00 0.00 0.00--
Debt-to-Capital Ratio
0.00 0.00 0.00--
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00--
Financial Leverage Ratio
1.73 -1.95 -0.71--
Debt Service Coverage Ratio
4.26 0.00 0.00--
Interest Coverage Ratio
4.72 0.00 0.00--
Debt to Market Cap
0.00 0.00 0.00--
Interest Debt Per Share
-0.42 0.00 0.00--
Net Debt to EBITDA
3.18 -0.39 0.89--
Profitability Margins
Gross Profit Margin
0.00%0.00%0.00%--
EBIT Margin
0.00%0.00%0.00%--
EBITDA Margin
0.00%0.00%0.00%--
Operating Profit Margin
0.00%0.00%0.00%--
Pretax Profit Margin
0.00%0.00%0.00%--
Net Profit Margin
0.00%0.00%0.00%--
Continuous Operations Profit Margin
0.00%0.00%0.00%--
Net Income Per EBT
100.00%100.00%96.41%--
EBT Per EBIT
168.99%-157.48%158.41%--
Return on Assets (ROA)
-55.91%247.63%-166.74%--
Return on Equity (ROE)
-73.14%-481.73%118.89%--
Return on Capital Employed (ROCE)
-39.11%-228.78%-167.94%--
Return on Invested Capital (ROIC)
-39.11%-228.78%-161.91%--
Return on Tangible Assets
-55.91%247.63%-166.74%--
Earnings Yield
-4.07%9.80%-14.44%--
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00--
Payables Turnover
0.00 0.00 0.00--
Inventory Turnover
0.00 0.00 0.00--
Fixed Asset Turnover
0.00 0.00 0.00--
Asset Turnover
0.00 0.00 0.00--
Working Capital Turnover Ratio
0.00 0.00 0.00--
Cash Conversion Cycle
0.00 0.00 0.00--
Days of Sales Outstanding
0.00 0.00 0.00--
Days of Inventory Outstanding
0.00 0.00 0.00--
Days of Payables Outstanding
0.00 0.00 0.00--
Operating Cycle
0.00 0.00 0.00--
Cash Flow Ratios
Operating Cash Flow Per Share
-0.77 -1.22 -1.32--
Free Cash Flow Per Share
-0.77 -1.22 -1.32--
CapEx Per Share
<0.01 0.00 0.00--
Free Cash Flow to Operating Cash Flow
1.00 1.00 1.00--
Dividend Paid and CapEx Coverage Ratio
-657.38 0.00 0.00--
Capital Expenditure Coverage Ratio
-657.38 0.00 0.00--
Operating Cash Flow Coverage Ratio
0.00 0.00 0.00--
Operating Cash Flow to Sales Ratio
0.00 0.00 0.00--
Free Cash Flow Yield
-0.87%-7.18%-7.78%--
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-24.52 10.21 -6.92--
Price-to-Sales (P/S) Ratio
0.00 0.00 0.00--
Price-to-Book (P/B) Ratio
23.72 -49.17 -8.23--
Price-to-Free Cash Flow (P/FCF) Ratio
-114.70 -13.92 -12.85--
Price-to-Operating Cash Flow Ratio
-107.38 -13.92 -12.85--
Price-to-Earnings Growth (PEG) Ratio
-1.61 -0.06 0.00--
Price-to-Fair Value
23.72 -49.17 -8.23--
Enterprise Value Multiple
-45.92 9.81 -9.68--
Enterprise Value
919.40M 183.41M 174.71M--
EV to EBITDA
-45.98 9.81 -9.68--
EV to Sales
0.00 0.00 0.00--
EV to Free Cash Flow
-107.42 -13.38 -11.77--
EV to Operating Cash Flow
-107.58 -13.38 -11.77--
Tangible Book Value Per Share
3.50 -0.35 -2.07--
Shareholders’ Equity Per Share
3.50 -0.35 -2.07--
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 0.04--
Revenue Per Share
0.00 0.00 0.00--
Net Income Per Share
-3.38 1.67 -2.46--
Tax Burden
1.00 1.00 0.96--
Interest Burden
1.87 1.00 1.58--
Research & Development to Revenue
0.00 0.00 0.00--
SG&A to Revenue
0.00 0.00 0.00--
Stock-Based Compensation to Revenue
0.00 0.00 0.00--
Income Quality
0.24 -0.73 0.54--
Currency in USD